Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...

Québec City-based biotechnology startup 9Bio is developing a platform for designing drugs that target tumours and spare ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...

Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

Moreover, Merck has initiated a Phase 3 clinical trial to evaluate its dengue vaccine candidate, enrolling approximately 12,000 children, marking a significant step in its vaccine development program.

Editor’s note: This story was updated at 8:47 a.m. June 19, 2025, to note that Merck Manuals – a separate entity from Merck – launched the new tool.